We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: T-Mobile US, NextEra Energy, Amgen, 3M and Itau Unibanco Holding
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 9, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: T-Mobile US, Inc. (TMUS - Free Report) , NextEra Energy, Inc. (NEE - Free Report) , Amgen Inc. (AMGN - Free Report) , 3M Co. (MMM - Free Report) and Itaú Unibanco Holding S.A. (ITUB - Free Report)
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for T-Mobile, NextEra and Amgen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc., NextEra Energy, Inc. and Amgen Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
T-Mobile shares have outperformed the Zacks Wireless National industry over the past year (+8.8% vs. -11.5%). The company reported solid second-quarter 2022 results with healthy customer growth driven by diligent execution of operational plans. It has raised the guidance for 2022 across the board. It is on track to complete the Sprint customer network decommissioning by the year-end.
The company has augmented its 5G footprint in the country by introducing 5G Home Internet services in several states. Its Extended Range 5G covers 320 million people. The Ultra Capacity 5G covers 235 million people.
However, it operates in a fiercely competitive and almost saturated U.S. telecom market that lowers its growth potential to some extent. Several promotional activities to lure additional customers are further eroding the profitability of the company. Furthermore the costs incurred to gain customers and enhance revenues have not yet been rewarded to shareholders
NextEra Energy shares have gained +7.0% over the past year against the Zacks Utility - Electric Power industry's gain of +11.9%. The company through the proper execution of organic projects and strategic acquisitions, is expanding its operations. NextEra Energy currently has a lot of renewable projects in its backlog and renewable project backlog is rising every quarter, which is aiding the company in cutting emissions.
The merger of Gulf Power and FPL strengthens NextEra Energy's position in Florida. Improving Florida economy and FPL's reliable services are expanding its customer volume every quarter. NextEra Energy has ample liquidity to meet its near-term debt obligations.
However, the nature of its business is subject to complex federal, state and other regulations. Unfavorable weather conditions and an increase in supply costs adversely impact earnings.
Amgen shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+17.2% vs. -40.1%). The company's key drugs like Prolia, Repatha and Xgeva are driving sales. Amgen is rapidly advancing its robust pipeline of early and late-stage assets. New drugs Lumakras and Tezspire, are off to an encouraging start.
Label expansion studies on Lumakras are progressing rapidly. The acquisition of ChemoCentryx, if successfully closed, will add a strategic new growth asset in Tavneos to Amgen's portfolio. Amgen boasts a strong biosimilars portfolio with potential new products expected to drive long-term growth.
However, increased pricing headwinds and competitive pressure are hurting sales of many of Amgen's products including some biosimilars. Also, increasing competition for its legacy products is hurting the sales. The IRS tax litigation is an overhang on Amgen shares.
Other noteworthy reports we are featuring today include 3M Co. and Itaú Unibanco Holding S.A..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: T-Mobile US, NextEra Energy, Amgen, 3M and Itau Unibanco Holding
For Immediate Release
Chicago, IL – September 9, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: T-Mobile US, Inc. (TMUS - Free Report) , NextEra Energy, Inc. (NEE - Free Report) , Amgen Inc. (AMGN - Free Report) , 3M Co. (MMM - Free Report) and Itaú Unibanco Holding S.A. (ITUB - Free Report)
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for T-Mobile, NextEra and Amgen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc., NextEra Energy, Inc. and Amgen Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
T-Mobile shares have outperformed the Zacks Wireless National industry over the past year (+8.8% vs. -11.5%). The company reported solid second-quarter 2022 results with healthy customer growth driven by diligent execution of operational plans. It has raised the guidance for 2022 across the board. It is on track to complete the Sprint customer network decommissioning by the year-end.
The company has augmented its 5G footprint in the country by introducing 5G Home Internet services in several states. Its Extended Range 5G covers 320 million people. The Ultra Capacity 5G covers 235 million people.
However, it operates in a fiercely competitive and almost saturated U.S. telecom market that lowers its growth potential to some extent. Several promotional activities to lure additional customers are further eroding the profitability of the company. Furthermore the costs incurred to gain customers and enhance revenues have not yet been rewarded to shareholders
(You can read the full research report on T-Mobile here >>>)
NextEra Energy shares have gained +7.0% over the past year against the Zacks Utility - Electric Power industry's gain of +11.9%. The company through the proper execution of organic projects and strategic acquisitions, is expanding its operations. NextEra Energy currently has a lot of renewable projects in its backlog and renewable project backlog is rising every quarter, which is aiding the company in cutting emissions.
The merger of Gulf Power and FPL strengthens NextEra Energy's position in Florida. Improving Florida economy and FPL's reliable services are expanding its customer volume every quarter. NextEra Energy has ample liquidity to meet its near-term debt obligations.
However, the nature of its business is subject to complex federal, state and other regulations. Unfavorable weather conditions and an increase in supply costs adversely impact earnings.
(You can read the full research report on NextEra Energy here >>>)
Amgen shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+17.2% vs. -40.1%). The company's key drugs like Prolia, Repatha and Xgeva are driving sales. Amgen is rapidly advancing its robust pipeline of early and late-stage assets. New drugs Lumakras and Tezspire, are off to an encouraging start.
Label expansion studies on Lumakras are progressing rapidly. The acquisition of ChemoCentryx, if successfully closed, will add a strategic new growth asset in Tavneos to Amgen's portfolio. Amgen boasts a strong biosimilars portfolio with potential new products expected to drive long-term growth.
However, increased pricing headwinds and competitive pressure are hurting sales of many of Amgen's products including some biosimilars. Also, increasing competition for its legacy products is hurting the sales. The IRS tax litigation is an overhang on Amgen shares.
(You can read the full research report on Amgen here >>>)
Other noteworthy reports we are featuring today include 3M Co. and Itaú Unibanco Holding S.A..
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.